Global Tourette Syndrome Treatment Market Report 2024

The tourette syndrome treatment market size has grown strongly in recent years. It will grow from $2.23 billion in 2023 to $2.37 billion in 2024 at a compound annual growth rate (CAGR) of 6.3%. The increase during the historic period can be attributed to advancements in pharmacotherapy, increased clinical research and understanding, the development of supportive therapies, enhancements in diagnosis and awareness, and the issuance of regulatory approvals and guidelines.

The tourette syndrome treatment market size is expected to see strong growth in the next few years. It will grow to $3.04 billion in 2028 at a compound annual growth rate (CAGR) of 6.4%. The rise in the forecast period can be attributed to advancements in precision medicine, the expansion of telehealth services, the integration of digital health solutions, increased funding for research, and the growing popularity of complementary and alternative therapies. Major trends expected in this period include advances in gene therapy, broader access to care, non-pharmacological interventions, global collaborative initiatives, and the emergence of behavioral therapies.

The anticipated rise in healthcare spending is set to drive growth in the tourette syndrome treatment market. Healthcare spending encompasses all expenses on healthcare services and products, including treatments, medications, hospital stays, and preventive care, over a specific period, reflecting the overall healthcare costs within a population. This increase is fueled by the escalating costs of advanced medical technologies, aging populations, and the prevalence of chronic illnesses. In Tourette syndrome treatment, healthcare spending goes towards developing advanced diagnostic tools, medications, and behavioral therapies. It also supports ongoing research, patient education, and access to specialized care. For example, as reported by the National Institutes of Health in January 2024, healthcare spending in the US grew by 4.1% in 2022 to reach $4.5 trillion, marking a faster growth rate than the 3.2% increase seen in 2021. Consequently, the surge in healthcare spending is propelling the tourette syndrome treatment market forward.

Key players in the tourette syndrome treatment market are concentrating on creating cutting-edge products such as wearable neuromodulation devices to gain a competitive advantage. These devices are portable electronic tools designed to administer targeted electrical or magnetic stimulation to specific nerves or brain regions, modulating neural activity. They are commonly used to treat neurological disorders, manage pain, or enhance cognitive functions. For instance, in August 2021, Neurotherapeutics Solutions Ltd., a UK-based medical device company, introduced a wearable neuromodulation device tailored to alleviate tourette's syndrome symptoms. This stimulation aims to synchronize rhythmic electrical brain activity linked with movement suppression, ultimately decreasing tic frequency, intensity, and urge-to-tic in individuals with tourette syndrome.

In April 2022, Saladax Biomedical Inc., a US-based company specializing in therapeutic drug monitoring (TDM) assays, acquired a patent portfolio related to antipsychotic drug testing from Janssen Pharmaceutica NV. for an undisclosed sum. This acquisition positions Saladax Biomedical to potentially enhance diagnostic tests and treatment approaches for Tourette syndrome by leveraging Janssen Pharmaceutica's antipsychotic drug intellectual property. Janssen Pharmaceutica NV., based in Belgium, is a key player in manufacturing, marketing, and distributing antipsychotic drugs utilized in treating tourette syndrome.

Major companies operating in the tourette syndrome treatment market are F Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb, AstraZeneca PLC, Novartis International AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Viatris Inc., Otsuka Pharmaceutical Co. Ltd., Biogen Inc., Eisai Co. Ltd., Jazz Pharmaceuticals plc, Mitsubishi Tanabe Pharma Corporation, Kyowa Kirin Co. Ltd., Amneal Pharmaceuticals, Mallinckrodt Pharmaceuticals, Neurocrine Biosciences, Sunovion Pharmaceuticals Inc., Supernus Pharmaceuticals, Lundbeck AS, Voyager Therapeutics Inc., NeuroSigma Inc.

North America was the largest region in the tourette syndrome treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tourette syndrome treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the tourette syndrome treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tourette syndrome treatment involves managing symptoms such as tics and behavioral issues through a variety of approaches, including medication, behavioral therapies, and supportive services. The goal is to decrease symptom frequency and severity while enhancing the overall quality of life for individuals with Tourette syndrome.

The main classes of drugs used in tourette syndrome treatment include antiadrenergic agents, antipsychotic agents, atypical antipsychotic agents, carbonic anhydrase inhibitors, anticonvulsants, and others. Antiadrenergic agents work by blocking or inhibiting the effects of adrenaline and noradrenaline. These medications are available through different channels such as hospital pharmacies, retail pharmacies, and online pharmacies, and are utilized in both pediatric and adult contexts.

The tourette syndrome treatment market research report is one of a series of new reports that provides tourette syndrome treatment market statistics, including tourette syndrome treatment industry global market size, regional shares, competitors with a tourette syndrome treatment market share, detailed tourette syndrome treatment market segments, market trends and opportunities, and any further data you may need to thrive in the tourette syndrome treatment industry. This tourette syndrome treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The tourette syndrome treatment market consists of revenues earned by entities by providing services, such as pharmacotherapy, behavioral therapies, neurostimulation techniques, and supportive services used during the process. The market value includes the value of related goods sold by the service provider or included within the service offering. The Tourette syndrome treatment market also includes sales of antipsychotics, wrist devices, and non-antipsychotic medications. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.